ZITHROMAX

Compare ZITHROMAX  to:
Compare
Compare

Generic Name for ZITHROMAX

Azithromycin (as dihydrate) 250mg, 500mg, 600mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ZITHROMAX

Macrolide (azalide).

Manufacturer of ZITHROMAX

Pfizer Labs

Indications for ZITHROMAX

Mild to moderate susceptible infections including acute bacterial exacerbations of COPD, acute bacterial sinusitis, acute otitis media, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure, urethritis, cervicitis, chancroid in men. Mycobacterium avium complex (MAC) disease: see literature.

Adult dose for ZITHROMAX

Use packets only for doses equal to 1gram. COPD: 500mg once daily for 3 days; or 500mg once daily for 1 day, then 250mg once daily for 4 days. Sinusitis: 500mg once daily for 3 days. Community-acquired pneumonia, pharyngitis/tonsillitis, skin and skin structure: 500mg once daily for 1 day, then 250mg once daily for 4 days. Nongonococcal urethritis, cervicitis, chancroid: 1g as a single dose. Urethritis, cervicitis due to N. gonorrhoeae: 2g as a single dose. MAC: see literature.

Children's dosing for ZITHROMAX

Use oral susp (not packets). Otitis media: <6 months: not recommended; ≥6 months: 30mg/kg as a single dose (max 1.5g); or 10mg/kg (max 500mg) once daily for 3 days; or 10mg/kg (max 500mg) once then 5mg/kg (max 250mg) per day for 4 days. Sinusitis: <6 months: not recommended; ≥6 months: 10mg/kg (max 500mg) once daily for 3 days. Community-acquired pneumonia: <6 months: not recommended; ≥6 months: 10mg/kg (max 500mg) once daily for 1 day, then 5mg/kg (max 250mg) once daily for 4 days. Pharyngitis/tonsillitis: <2 yrs: not recommended; ≥2 yrs: 12mg/kg (max 500mg) once daily for 5 days. MAC prophylaxis: see literature.

Also:

Contraindications for ZITHROMAX

Ketolide or related allergy.

Precautions for ZITHROMAX

Pneumonia: oral treatment is for mild, community-acquired cases suitable for outpatient therapy only. Hepatic or renal impairment. Hypersensitivity reactions may recur after initial successful symptomatic treatment. Pregnancy (Cat.B). Nursing mothers.

Interactions for ZITHROMAX

Avoid concomitant aluminum- or magnesium-containing antacids. Monitor digoxin, cyclosporine, ergots, hexobarbital, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir.

Adverse Reactions for ZITHROMAX

GI upset, abdominal pain, rash, chest pain; rare: allergy (eg, angioedema, cholestatic jaundice).

How is ZITHROMAX supplied?

Tabs—30
Z-Pak (6 x 250mg tabs)—3
Tri-Pak (3 x 500mg tabs)—3
Susp 100mg/5mL—15mL
200mg/5mL—15mL, 22.5mL, 30mL
Single Dose Packets—3, 10
Inj (500mg vials)—10

Related Disease:

Infections, bacterial~systemic antiinfectives
Pneumonia
Sinusitis

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.